Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: Could cost weigh in evaluation?

Journal of Oncology Practice

Volumn 8, Issue 4, 2012, Pages 224-230

  Guirgis, Helmy M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; TRASTUZUMAB;

ARTICLE; BODY WEIGHT; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DRUG COST; HUMAN; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SCORING SYSTEM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HEALTH CARE COSTS; HUMANS; LUNG NEOPLASMS; QUINAZOLINES;

EID: 84870352045     PISSN: 15547477     EISSN: 1935469X     Source Type: Journal    
DOI: 10.1200/JOP.2011.000390     Document Type: Article

References (54)

1. Negrier S, Remak E, Brown R, et al: Economic evaluation of sunitinib vs. interferon-alfa (Ifn-alfa) in first line metastatic renal cell carcinoma (mRCC). Presented at the 14th European Cancer Conference, 2007 (poster 4514)
2. Dale, W, Fojo, T. Should oncologists discuss the cost of treatment with patients? Hemonctoday: Clinical News in Hemotology and Oncology. www.hemonctoday.com/articlePrint.aspx?type=print&rID=43594
3. Benedict A, Charbonneau C, Hidi J, et al: Economic evaluation of sunitinib, sorafenib, bevacizumab/Interferon-alfa or temsirolimus in 1st-line treatment of metastatic renal cell carcinoma (mRCC): An indirect comparison. J Clin Oncol 26, 2008 (suppl; abstract 5048)
4. Tappenden P, Jones R, Paisley S, et al: Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 11:1-146, 2007
5. Grothey A, Hedrick EE, Mass RD, et al: Response-independent survival benefit in metastatic colorectal cancer: A comparative analysis of N9741 and AVF2107. J Clin Oncol 26:183-189, 2008
6. Soria JC, Massard C, Le Chevalier T, et al: Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? Ann Oncol 21: 2324-2332, 2010
7. Edgerly M, Fojo T: Is there room for improvement in adverse event reporting in the era of targeted therapies? J Natl Cancer Inst 100:240-242, 2008 (Pubitemid 351480535)
8. Hillner BE, Smith TJ: Efficacy does not necessarily translate to cost-effectiveness: A case study in the challenges associated with 21st-century cancer drug pricing. J Clin Oncol 27:2111-2113, 2009
9. Miller K, Wang M, Gralow J, et al: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357:2666-2676, 2007
10. Miles DW, Chan A, Dirix LY, et al: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor 2-negative metastatic breast cancer. J Clin Oncol 28:3239-3247, 2010
11. Robert NJ, Dieras V, Glaspy J, et al: RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 29: 1252-1260, 2011
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al: Erlotinib in previously treated non-small-cell cancer. N Engl J Med 353:123-132, 2005 (Pubitemid 41058344)
13. Bradbury PA, Tu D, Seymour L, et al: Economic analysis: Randomized placebo-controlled clinical trial of erlotinib in advanced non-small cell lung cancer. J Natl Cancer Inst 102:298-306, 2010
14. Hoos A, Parmiani G, Hege K, et al: Cancer Vaccine Clinical Trial Working Group. A clinical development paradigm for cancer vaccines and related biologics J Immunother 30:1-15, 2007 (Pubitemid 46052199)
15. Sandler A, Gray R, Perry MC, et al: Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355:2542-2550, 2006 (Pubitemid 44917502)
16. Manegold C, von Pawel J, Zatloukal P, et al: BO17704 (AVAIL). A phase III randomized study of first-line bevacizumab combined with cisplatin/gemcitabine in chemotherapy-naïve patients with advanced recurrent non-squamous cell lung cancer (NSCLC). Ann Oncol 19:vii1-vii4, 2008 (suppl 8)
17. Ranpura V, Hapani S, Wu S, et al: Treatment-related mortality with bevacizumab in cancer patients: A meta-analysis. JAMA 305:487-494, 2011
18. Wacker B, Nagrani T, Weinberg J, et al: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921, 2007 (Pubitemid 47037599)
19. Wu S, Chen JJ, Kudelka A, et al: Incidence and risk of hypertension with Sorafenib in patients with cancer: A systematic review and meta-analysis. Lancet Oncol 9:117-123, 2008
20. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335-2342, 2004 (Pubitemid 38702844)
21. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2-positive metastatic breast cancer that overexpresses HER2. N Engl J Med 144:788-792, 2001
22. Santoro A, Gullo G: Trastuzumab beyond progression: A challenge to translational oncology? Ann Oncol 21:2131-2134, 2010
23. Montemurro F, Redana S, Geuna E, et al: Trastuzumab beyond progression in retrospective analysis: An issue of equal opportunities. Oncologist 16:534-536, 2011
24. Kaufman B, Mackey JR, Clemens MR, et al: Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: Results from the randomized phase III TAnDEM study. J Clin Oncol 27:5529-5537, 2009
25. Davidoff AJ, Tang M, Seal B, et al: Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 28: 2191-2197, 2010
26. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced nonsmall- cell cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459- 2465, 1998
27. Pirker R, Szczesna A, von Pawel J, et al. A randomized multicenter phase III trial of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small lung cancer NSCLC (FLEX). J Clin Oncol 26 (May 20, Suppl 3), 2008
28. Pirker R: Results of phase III study of patients with stage IIIb/IV disease and high epidermal growth factor receptor (EGFR) expression [FLEX]. Presented at the 14th World Conference on Lung Cancer, Amsterdam, the Netherlands, July 3-7, 2011 (abstr 1557)
29. Sandler A, Jing Yi, Dahlberg S, et al: Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer. J Thor Oncol 5:1416-1423, 2010
30. Nadler E, Yu E, Ravelo A, et al: Bevacizumab treatment to progression after chemotherapy: Outcome from a U.S. community practice network. Oncologist 16:486-496, 2011
31. Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362:2381-2388, 2010
32. Yang C-H, Fukuoka M, Mok TS, et al: Final overall survival (OS) results from a phase III, randomised, open-label, first-line study of gefitinib (G) v carboplatin/paclitaxel (C/P) in clinically selected patients with advanced nonsmall cell lung cancer (NSCLC) in Asia (IPASS). Presented at the 35th European Society for Medical Oncology (ESMO) Congress, Milan, Italy, October 8-12, 2010 (abstr LBA2)
33. Chen G, Feng J, Liu Xq, et al: Efficacy results from the randomised phase III OPTIMAL (CTONG 0802) study comparing first-line erlotinib versus carboplatin (CBDCA) plus gemcitabine (GEM), in Chinese advanced non-small-cell lung cancer (NSCLC) patients (pts) with EGFR activating mutations. Presented at the 35th European Society for Medical Oncology (ESMO) Congress, Milan, Italy, October 8-12, 2010 (abstr LBA13)
34. Ciuleanu T, Brodowics T, Zielinski C, et al: Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomized, double blind, phase 3 study. Lancet 374: 1432-1439, 2009
35. Cappuzzo F, Ciuleanu T, Stelmakh L, et al: SATRUN: A double-blind randomized phase III study of maintenance erlotinib versus placebo following nonprogression with first-line platinum-based chemotherapy in patients with advanced NSCLC. J Clin Oncol 27:407s, 2009 (suppl; abstr 8001)
36. Coudert B, Ciuieanu T, Park K, et al: Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Ann Oncol [epub ahead of print on May 24, 2011]
37. Kelley RK, Venook AP: Nonadherance to imatinib during an economic downturn. N Engl J Med 363:596-598, 2010
38. Malin JL: Wrestling with the high price of cancer care: Should we control costs by individuals' ability to pay or society's willingness to pay? J Clin Oncol 28:3212-3213, 2010
39. Mason A, Drummond M, Ramsey S: Comparison of anticancer drugs coverage decisions in the United States and United Kingdom: Does the evidence support the rhetoric? J Clin Oncol 28:3234-3238, 2010
40. Fidias P, Novello S: Strategies for prolonged therapy in patients with advanced non-Small-Cell lung cancer. J Clin Oncol 28:5116-5123, 2010
41. Ellis LM, Haller DG: Bevacizumab beyond progression: Does it make sense? J Clin Oncol 26: 5313-5315, 2008
42. Grothey A, Surgrue MM, Purdie DM, et al: Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRITE). J Clin Oncol 16:3212-3217, 2008
43. Grothey A: The role of chemotherapy in stage IV colorectal cancer: Focus on combinations with biological agents and conversion therapy. Commun Oncol 5:3-8, 2008
44. Karapetis CS, Khambata-Ford S, Derek DJ et al. K-ras Mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008
45. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004 (Pubitemid 38637993)
46. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361:947-957, 2009
47. Lopes G, Segel JE, Tan DSW, et al: Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. Cancer doi: 10.1002/cncr.26372
48. National Comprehensive Cancer Network: National Comprehensive Cancer Network guidelines for non-small cell lung cancer. www.nccn.org/professionals/ physician-gls/f-guidelines.asp
49. Guirgis HM: A perspective on tyrosine kinase inhibitors in gastrointestinal stromal tumors and cancer: Past and present with emphasis on future and cost. Cancer Therapy 5:417-436, 2007
50. Twelves C, Cortes J, Vahdat LT et al: Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer Clin Breast Cancer 10:160-163, 2010
51. Reed SD, Li Y, Anstrom KJ, et al: Cost effectiveness of ixabepilone for metastatic breast carcinoma progressing after anthracycline and taxane treatment. J Clin Oncol 27:2185-2191, 2009
52. Thomas ES, Gomez HL, Li RK, et al: Ixebepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007 (Pubitemid 350232252)
53. Mckee AE, Farrell AT, Pazdur R, et al: The role of the U.S Food and Drug Administration review process: Clinical trial endpoints in oncology. Oncologist 15:13-18, 2010 (suppl 1)
54. Ferrusi IL, Leighl NB, Kulin NA, et al: Do economic evaluations of targeted therapy provide support for decision makers? J Oncol Pract 7:36s-45s, 2011